To overcome the societal and financial burden of cardiovascular disease, a thorough understandingof the molecular and cellular programmes governing cardiac and coronary vascular development isvital. Cre-mediated genetic tracing in various models has provided valuable insight into cell-lineagecontribution and inductive cues required for cardiac morphogenesis. Using mouse models, we haveidentified the transmembrane protein Cysteine-Rich Transmembrane BMP Regulator-1 (Crim1) asan essential protein for numerous aspects of heart development. The presence of six Cysteine-RichRepeats (CRRs) in Crim1 render it to be a versatile molecule – these have been shown to bind awide range of growth factors when Crim1 is co-expressed in the same cell as the growth factor(Wilkinson et al., 2003, Wilkinson et al., 2007). The main objective of this thesis is to examine therole that Crim1 plays both temporally and spatially during heart development, and how it functionsin tandem with other factors to ensure the progression of this critical process.Crim1 is strongly expressed in the proepicardium (PE), epicardium, coronary vascular smoothmuscle cells and, to a weaker extent, in coronary endothelial cells (Pennisi et al., 2007).Interestingly, Crim1 mutant homozygotes die perinatally on a C57BL6 background (Chiu et al.,2012). Loss of Crim1 function leads to a reduced ventricular size and hypoplastic ventricularcompact myocardium, and abnormal epicardial morphology including blebbing and a loss of theregular, cobblestone appearance of the epicardium. Furthermore, epicardium-restricted deletion ofCrim1 resulted in increased epicardial epithelial-to-mesenchymal transition (EMT) and invasion ofthe myocardium, while primary epicardial cells lacking Crim1 displayed an increased migration.Growth factors like TGFβs are known to promote epicardial EMT; however, we observed aparadoxical reduction in epicardial TGFβ signalling in Crim1 mutant embryos. Interestingly, thereappeared to be an accumulation of β-catenin, a cell-adhesion molecule present at cadherindependentjunctional complexes in epithelial cells, at epicardial cell-cell junctions, suggesting aninteraction with Crim1 to promote stabilization of these junctions. There was also an increase in thelevel of phospho-ERK1/2 in the ventricular compact myocardium of mutants, though phospho-AKTlevels remained unchanged. This indicates a cell-autonomous role for Crim1 in controllingepicardial migration, EMT and invasion, and a potential paracrine role in regulating myocardialdevelopment, likely through regulation of epicardium derived factors.Another notable defect observed in the absence of Crim1 is that the coronary vasculature alsoappears to be malformed. We found a reduction in coronary vascular endothelial cell endowment in both ventricles, in Crim1Δflox/Δflox homozygotes and in endothelium-restricted mutants, identifyinga cell-autonomous role for Crim1. To further study Crim1 function in vitro, lentiviral small hairpinribonucleic acid (shRNA) targeting the CRIM1 gene was transduced into Human CardiacMicrovascular Endothelial Cells (HCMVECs), with a knockdown of more than 70% achieved at thetranscript level. Trypan Blue viability assays in both HCMVECs and Human Umbilical VeinEndothelial Cells (HUVECs) indicate reduced viability in the absence of CRIM1. Protein lysatesobtained from both Crim1-knockdown HCMVECs and HUVECs indicate a reduction in phosphoSMAD1/5levels, but no change in phospho-ERK1/2 and phospho-AKT levels.We also sought to understand the role of Crim1 in growth factor modulation in endothelial cells invivo. There was a decrease in phospho-SMAD1/5 activity in endothelial cells from ventricles ofCrim1Δflox/Δflox homozygotes, suggesting a dysregulation of TGFβ/BMP signalling in these cells,confirming our in vitro data. However, there was an increase in endothelial phospho-SMAD1/5levels in ventricles of Crim1Flox/Flox; Tie2-Cre hearts, indicating a possible paracrine role for theother resident cells of the ventricular myocardium that retain Crim1 function.cDNA synthesised from HCMVECs that had lost Crim1 was then used in a human endothelial cellbiology array. This revealed an upregulation of genes involved in increased inflammatory responseand cell death, and, an increased probability of disease states including vascular lesions, infarctionand heart failure, upon Ingenuity Pathway Analysis. Collectively, we illustrate a cell-autonomousrole for Crim1 in the development of coronary vascular endothelial cells, in vivo and in vitro.We further report for the first time, that CRIM1 is able to bind Insulin-like Growth Factors (IGFs).This was shown by means of co-immunoprecipitation experiments, and reveals that the IGFBPdomain of CRIM1, and CRRs 3-6 are responsible for this binding. Moreover, in HCMVECs lackingCRIM1, phosphorylation of the IGF-1 receptor was decreased, indicating the ability of CRIM1 toregulate IGF signalling.Our findings thus provide a platform for understanding how Crim1 functions in both the early andlate stages of embryonic heart development in vivo. Many of these findings are mimicked in vitro,most significantly in the context of growth factor modulation in human cardiac microvascularendothelial cells, and aids in understanding the pathogenesis of disease states. This indicatestranslational relevance to humans, making the study of CRIM1 an exciting new avenue for futureresearch in the field of cardiac development.